Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
Authors
Keywords
Relapsed acute myeloid leukemia, Down syndrome-associated AML, Chemoresistance, Disulfiram, Bortezomib, Cytarabine, ALDH
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 36, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-02-01
DOI
10.1186/s13046-017-0493-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer
- (2016) Ji Young Kim et al. CANCER LETTERS
- Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma
- (2016) X. Lun et al. CLINICAL CANCER RESEARCH
- Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome
- (2016) Carina Scheer et al. PEDIATRIC BLOOD & CANCER
- The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders
- (2016) Rebecca Citrin et al. Expert Review of Hematology
- Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells
- (2016) Xinwei Liu et al. Oncotarget
- Pediatric AML: From Biology to Clinical Management
- (2015) Jasmijn de Rooij et al. Journal of Clinical Medicine
- High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells
- (2015) Parvinder Hothi et al. Oncotarget
- Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism
- (2015) Ahmed Waraky et al. Oncotarget
- Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells
- (2014) Lincan Duan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia
- (2014) J. Timothy Caldwell et al. PEDIATRIC BLOOD & CANCER
- A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group
- (2014) Terzah M. Horton et al. PEDIATRIC BLOOD & CANCER
- Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners
- (2014) Tetsuhiro Chiba et al. PLoS One
- Prognosis and management of acute myeloid leukemia in patients with Down syndrome
- (2014) J Timothy Caldwell et al. Expert Review of Hematology
- Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome
- (2013) Johann K. Hitzler et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells
- (2013) P Liu et al. BRITISH JOURNAL OF CANCER
- Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage
- (2013) A. Paranjpe et al. CARCINOGENESIS
- The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma
- (2012) Grit Hutter et al. ANNALS OF HEMATOLOGY
- Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells
- (2012) P Liu et al. BRITISH JOURNAL OF CANCER
- Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies
- (2012) Concetta Conticello et al. INTERNATIONAL JOURNAL OF CANCER
- Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells
- (2012) Zdenek Skrott et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Targeting Myelogenous Leukemia Stem Cells: Role of the Circulation
- (2012) Jane Liesveld Frontiers in Oncology
- Disulfiram/copper complex activated JNK/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells
- (2011) Bing Xu et al. BLOOD CELLS MOLECULES AND DISEASES
- Inhibition of proteasome deubiquitinating activity as a new cancer therapy
- (2011) Pádraig D'Arcy et al. NATURE MEDICINE
- The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
- (2011) Marianne van Dijk et al. Cancers
- Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials
- (2010) A Sander et al. LEUKEMIA
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
- (2008) E. Colado et al. HAEMATOLOGICA
- Ni(II), Cu(II), and Zn(II) Diethyldithiocarbamate Complexes Show Various Activities Against the Proteasome in Breast Cancer Cells
- (2008) Boris Cvek et al. JOURNAL OF MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More